These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 28059023)

  • 21. Long-term data on tacrolimus treatment in lupus nephritis.
    Yap DY; Ma MK; Mok MM; Kwan LP; Chan GC; Chan TM
    Rheumatology (Oxford); 2014 Dec; 53(12):2232-7. PubMed ID: 24996908
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination therapy of rituximab and mycophenolate mofetil in childhood lupus nephritis.
    Hogan J; Godron A; Baudouin V; Kwon T; Harambat J; Deschênes G; Niel O
    Pediatr Nephrol; 2018 Jan; 33(1):111-116. PubMed ID: 28780657
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinicopathological findings, treatment response and predictors of long-term outcome in a cohort of lupus nephritis patients managed according to the Euro-lupus regime: a retrospective analysis in Sri Lanka.
    Herath N; Ratnatunga N; Weerakoon K; Wazil A; Nanayakkara N
    BMC Res Notes; 2017 Feb; 10(1):80. PubMed ID: 28148285
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intensified, intermittent, low-dose intravenous cyclophosphamide together with oral alternate-day steroid therapy in lupus nephritis (long-term outcome).
    Calguneri M; Ozbalkan Z; Ozturk MA; Apras S; Ertenli AI; Kiraz S
    Clin Rheumatol; 2006 Nov; 25(6):782-8. PubMed ID: 16547692
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis.
    Ginzler EM; Dooley MA; Aranow C; Kim MY; Buyon J; Merrill JT; Petri M; Gilkeson GS; Wallace DJ; Weisman MH; Appel GB
    N Engl J Med; 2005 Nov; 353(21):2219-28. PubMed ID: 16306519
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunosuppressive therapy withdrawal after remission achievement in patients with lupus nephritis.
    Zen M; Fuzzi E; Loredo Martinez M; Depascale R; Fredi M; Gatto M; Larosa M; Saccon F; Iaccarino L; Doria A
    Rheumatology (Oxford); 2022 Feb; 61(2):688-695. PubMed ID: 33909900
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of renoprotective approaches for persistent proteinuria in lupus nephritis: more than just immunosuppression.
    Castro M; Ugolini-Lopes M; Borba EF; Bonfá E; Seguro LPC
    Lupus; 2018 Dec; 27(14):2215-2219. PubMed ID: 30394834
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mizoribine, tacrolimus, and corticosteroid combination therapy successfully induces remission in patients with lupus nephritis.
    Kagawa H; Hiromasa T; Hara T; Takaki A; Yamanaka R; Sada KE; Makino H
    Clin Exp Nephrol; 2012 Oct; 16(5):760-6. PubMed ID: 22492013
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cyclosporine A in treatment of membranous lupus nephropathy.
    Hu W; Liu Z; Shen S; Li S; Yao X; Chen H; Li L
    Chin Med J (Engl); 2003 Dec; 116(12):1827-30. PubMed ID: 14687467
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term follow-up of a randomised controlled trial of azathioprine/methylprednisolone versus cyclophosphamide in patients with proliferative lupus nephritis.
    Arends S; Grootscholten C; Derksen RH; Berger SP; de Sévaux RG; Voskuyl AE; Bijl M; Berden JH;
    Ann Rheum Dis; 2012 Jun; 71(6):966-73. PubMed ID: 22128082
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early-stage predictors for treatment responses in patients with active lupus nephritis.
    Liu G; Wang H; Le J; Lan L; Xu Y; Yang Y; Chen J; Han F
    Lupus; 2019 Mar; 28(3):283-289. PubMed ID: 30682900
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis.
    Illei GG; Austin HA; Crane M; Collins L; Gourley MF; Yarboro CH; Vaughan EM; Kuroiwa T; Danning CL; Steinberg AD; Klippel JH; Balow JE; Boumpas DT
    Ann Intern Med; 2001 Aug; 135(4):248-57. PubMed ID: 11511139
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glucocorticoid with or without additional immunosuppressant therapy for patients with lupus podocytopathy: a retrospective single-center study.
    Hu WX; Chen YH; Bao H; Liu ZZ; Wang SF; Zhang HT; Liu ZH
    Lupus; 2015 Sep; 24(10):1067-75. PubMed ID: 25819933
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment of proliferative lupus nephritis with leflunomide and steroid: a prospective multi-center controlled clinical trial].
    Cui TG; Hou FF; Ni ZH; Chen XM; Zhang FS; Zhu TY; Zhao XZ; Bao CD; Zhao MH; Wang GB; Qian JQ; Cai GY; Li YN; Lu FM; Mei CL; Zou WZ; Wang HY
    Zhonghua Nei Ke Za Zhi; 2005 Sep; 44(9):672-6. PubMed ID: 16202258
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis.
    Rathi M; Goyal A; Jaryal A; Sharma A; Gupta PK; Ramachandran R; Kumar V; Kohli HS; Sakhuja V; Jha V; Gupta KL
    Kidney Int; 2016 Jan; 89(1):235-42. PubMed ID: 26489028
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Laboratory and morphologic parameters in patients with lupus nephritis].
    Rasković S; Bogić M; Perić-Popadić A; Stefanović L; Arandjelović S; Jovicić Z; Bolpacić J; Tomić-Spirić V
    Srp Arh Celok Lek; 2002 Aug; 130 Suppl 3():38-41. PubMed ID: 12583312
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Renal outcome in patients with lupus nephritis using a steroid-free regimen of monthly intravenous cyclophosphamide: a prospective observational study.
    Fischer-Betz R; Chehab G; Sander O; Vordenbäumen S; Voiculescu A; Brinks R; Schneider M
    J Rheumatol; 2012 Nov; 39(11):2111-7. PubMed ID: 22984276
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Experience of Proteasome Inhibitor Bortezomib Regarding Efficacy and Safety in Severe Systemic Lupus Erythematosus: A Nationwide Study.
    Walhelm T; Gunnarsson I; Heijke R; Leonard D; Trysberg E; Eriksson P; Sjöwall C
    Front Immunol; 2021; 12():756941. PubMed ID: 34659263
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: mycophenolate mofetil or intravenous cyclophosphamide.
    Wang J; Hu W; Xie H; Zhang H; Chen H; Zeng C; Liu Z; Li L
    Lupus; 2007; 16(9):707-12. PubMed ID: 17728363
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-dose azathioprine pulse therapy as a new treatment option in patients with active Wegener's granulomatosis and lupus nephritis refractory or intolerant to cyclophosphamide.
    Benenson E; Fries JW; Heilig B; Pollok M; Rubbert A
    Clin Rheumatol; 2005 Jun; 24(3):251-7. PubMed ID: 15940558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.